Index -
P/E -
EPS (ttm) -2.58
Insider Own 4.89%
Shs Outstand 98.25M
Perf Week -22.54%
Market Cap 1.38B
Forward P/E 3.83
EPS next Y 3.67
Insider Trans -0.05%
Shs Float 93.47M
Perf Month -34.72%
Enterprise Value 2.20B
PEG -
EPS next Q 0.70
Inst Own 90.26%
Short Float 15.71%
Perf Quarter -73.91%
Income -248.39M
P/S 0.62
EPS this Y -256.61%
Inst Trans -0.90%
Short Ratio 2.48
Perf Half Y -88.20%
Sales 2.23B
P/B 1.21
EPS next Y 207.50%
ROA -7.43%
Short Interest 14.68M
Perf YTD -88.42%
Book/sh 11.63
P/C 2.65
EPS next 5Y 16.97%
ROE -23.61%
52W High 150.48 -90.65%
Perf Year -90.55%
Cash/sh 5.32
P/FCF -
EPS past 3/5Y - -
ROIC -9.99%
52W Low 16.88 -16.62%
Perf 3Y -82.21%
Dividend Est. -
EV/EBITDA -
Sales past 3/5Y 39.42% 37.94%
Gross Margin 80.07%
Volatility 15.99% 8.44%
Perf 5Y -91.66%
Dividend TTM -
EV/Sales 0.99
EPS Y/Y TTM -1881.09%
Oper. Margin -5.25%
ATR (14) 2.47
Perf 10Y -50.25%
Dividend Ex-Date -
Quick Ratio 2.46
Sales Y/Y TTM 59.15%
Profit Margin -11.12%
RSI (14) 30.81
Recom 2.30
Dividend Gr. 3/5Y - -
Current Ratio 4.02
EPS Q/Q -1361.33%
SMA20 -23.04%
Beta 0.46
Target Price 43.00
Payout 0.00%
Debt/Eq 1.18
Sales Q/Q 80.15%
SMA50 -51.58%
Rel Volume 12.96
Prev Close 21.97
Employees 1372
LT Debt/Eq 1.18
Earnings May 06 AMC
SMA200 -83.60%
Avg Volume 5.91M
Price 14.07
IPO Jun 04, 1997
Option/Short Yes / Yes
EPS/Sales Surpr. -43.44% 8.35%
Trades
Volume 76,568,720
Change -35.94%
Date
Action
Analyst
Rating Change
Price Target Change
Today Downgrade
Needham
Buy → Hold
Jun-20-25 Downgrade
William Blair
Outperform → Mkt Perform
Jun-18-25 Downgrade
TD Cowen
Buy → Hold
$24
Jun-17-25 Initiated
Wolfe Research
Peer Perform
Jun-16-25 Downgrade
Piper Sandler
Overweight → Neutral
$36
Jun-16-25 Downgrade
Morgan Stanley
Overweight → Equal-Weight
Jun-16-25 Downgrade
H.C. Wainwright
Neutral → Sell
$10
Jun-16-25 Downgrade
Cantor Fitzgerald
Overweight → Neutral
Jun-16-25 Downgrade
BofA Securities
Buy → Neutral
Jun-16-25 Downgrade
BMO Capital Markets
Outperform → Market Perform
$70
Jun-06-25 Upgrade
Scotiabank
Sector Perform → Sector Outperform
May-08-25 Downgrade
Evercore ISI
Outperform → In-line
$50
Apr-11-25 Initiated
Wells Fargo
Overweight
$115
Apr-02-25 Upgrade
H.C. Wainwright
Sell → Neutral
$75
Mar-31-25 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$161 → $87
Feb-11-25 Initiated
Deutsche Bank
Hold
$136
Nov-27-24 Reiterated
Needham
Buy
$205 → $202
Nov-25-24 Initiated
H.C. Wainwright
Sell
$80
Nov-07-24 Upgrade
Cantor Fitzgerald
Neutral → Overweight
$152 → $167
Oct-21-24 Initiated
Jefferies
Buy
$165
Show Previous Ratings
Today 07:54PM
07:39PM
06:42PM
(The Wall Street Journal)
05:57PM
04:32PM
04:17PM
Loading…
04:17PM
(Investor's Business Daily)
03:49PM
02:58PM
02:24PM
01:38PM
12:44PM
12:19PM
11:43AM
11:32AM
11:03AM
09:10AM
Loading…
09:10AM
(Investor's Business Daily)
08:20AM
08:17AM
07:48AM
07:06AM
05:39AM
Jul-17-25 05:04PM
(The Wall Street Journal) +19.53%
04:38PM
04:13PM
(Investor's Business Daily)
02:43PM
01:24PM
(The Wall Street Journal)
11:57AM
11:00AM
10:58AM
10:02AM
08:11AM
Loading…
08:11AM
(Pharmaceutical Technology)
06:03AM
05:24AM
05:18AM
04:41AM
Jul-16-25 11:34PM
(Investor's Business Daily)
05:39PM
05:30PM
(The Wall Street Journal)
05:00PM
04:01PM
12:23PM
12:18PM
Jul-15-25 08:58AM
Jul-11-25 09:00AM
Jul-10-25 01:51PM
Jun-30-25 06:26PM
Jun-27-25 08:15AM
Jun-25-25 01:33PM
(Investor's Business Daily) -8.01%
01:01PM
Jun-24-25 03:09PM
10:20AM
Jun-20-25 04:08PM
(Investor's Business Daily)
-6.03%
11:56AM
11:56AM
11:27AM
Jun-19-25 09:45AM
03:00AM
Jun-18-25 11:39AM
09:51AM
Jun-17-25 09:35AM
09:23AM
09:16AM
06:20AM
Jun-16-25 05:07PM
(The Wall Street Journal) -42.12%
04:19PM
(Investor's Business Daily)
04:13PM
04:05PM
(Associated Press Finance)
03:51PM
03:15PM
02:31PM
01:37PM
(The Wall Street Journal)
12:30PM
12:19PM
11:59AM
11:10AM
(Investor's Business Daily)
10:24AM
09:12AM
08:45AM
08:00AM
07:55AM
(Pharmaceutical Technology)
06:18AM
05:18AM
05:17AM
Jun-15-25 01:00AM
Jun-10-25 12:31PM
12:38AM
Jun-07-25 09:40AM
Jun-05-25 05:39PM
11:31AM
10:03AM
Jun-04-25 01:00PM
09:30AM
May-27-25 10:03AM
May-22-25 06:52AM
May-21-25 08:30AM
May-19-25 10:04AM
07:36AM
May-16-25 09:01AM
09:00AM
May-14-25 08:30AM
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Barry Richard Director May 16 '25 Option Exercise 32.63 12,350 402,981 2,966,667 May 19 07:32 AM Barry Richard Director May 13 '25 Option Exercise 19.23 20,246 389,359 2,954,317 May 15 07:00 AM Nicaise Claude Director Mar 12 '25 Option Exercise 25.18 9,746 245,404 30,303 Mar 13 08:00 PM Nicaise Claude Director Mar 12 '25 Sale 99.64 2,491 248,203 27,812 Mar 13 08:00 PM Nicaise Claude Director Mar 12 '25 Proposed Sale 99.65 2,491 248,226 Mar 12 05:33 PM Estepan Ian Michael Chief Financial Officer Jan 29 '25 Option Exercise 12.00 15,800 189,600 49,496 Jan 31 08:30 PM Wigzell Hans Lennart Rudolf Director Dec 12 '24 Option Exercise 13.71 10,500 143,955 33,340 Dec 16 08:00 PM Wigzell Hans Lennart Rudolf Director Dec 12 '24 Sale 124.84 10,500 1,310,820 22,840 Dec 16 08:00 PM Wigzell Hans Lennart Rudolf Director Dec 12 '24 Proposed Sale 124.80 10,500 1,310,400 Dec 12 05:06 PM Boor Kathryn Jean Director Dec 05 '24 Sale 125.55 1,636 205,400 5,880 Dec 06 08:00 PM Boor Kathryn Jean Director Dec 05 '24 Proposed Sale 125.55 1,636 205,400 Dec 05 04:18 PM Estepan Ian Michael Chief Financial Officer Aug 30 '24 Sale 137.36 5,985 822,100 33,946 Sep 03 08:00 PM Estepan Ian Michael Officer Aug 30 '24 Proposed Sale 137.37 5,985 822,130 Aug 30 05:03 PM Chambers Michael Andrew Director Aug 16 '24 Buy 133.80 37,038 4,955,728 284,034 Aug 20 08:00 AM